Neuropace Stock In The News
NPCE Stock | USD 8.51 0.01 0.12% |
The tone or emotional content of news articles related to Neuropace can affect its prices. Positive news sentiment can lead to an increase in demand for Neuropace's stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Neuropace's news coverage and content from conventional and social sources shows investors' bearish mood towards Neuropace. The specific impact of Neuropace news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Neuropace's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Neuropace headlines in addition to utilizing other, more conventional financial analysis modules. Check out Neuropace Backtesting and Neuropace Hype Analysis. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.
Neuropace |
Neuropace Today Top News and Investor Outlook
Neuropace Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Neuropace and other traded companies coverage. We help investors stay connected with Neuropace headlines for the 15th of May 2024 to make an informed investment decision based on correlating the impacts of news items on Neuropace Stock performance. Please note that trading solely based on the Neuropace hype is not for everyone as timely availability and quick action are needed to avoid losses.Neuropace stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Neuropace earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.
Neuropace Largest EPS Surprises
Earnings surprises can significantly impact Neuropace's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-11-10 | 2021-09-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2023-05-04 | 2023-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2024-03-05 | 2023-12-31 | -0.31 | -0.23 | 0.08 | 25 | ||
2022-08-11 | 2022-06-30 | -0.44 | -0.52 | -0.08 | 18 | ||
2023-08-08 | 2023-06-30 | -0.46 | -0.36 | 0.1 | 21 | ||
2022-03-10 | 2021-12-31 | -0.33 | -0.44 | -0.11 | 33 |
Neuropace Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Neuropace Stock. The global stock market is bullish. About 70% of major world exchanges and indexes are currently up. See today's market update for more information.14th of May 2024
NeuroPace to Participate in Two Healthcare Conferences in May at benzinga.com
10th of May 2024
NeuroPace First Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags at simplywall.st
9th of May 2024
NPCE Stock Earnings NeuroPace Meets EPS, Beats Revenue for Q1 2024 at investorplace.com
7th of May 2024
Globus Medical Q1 Earnings and Revenues Beat Estimates at zacks.com
3rd of May 2024
Disposition of 4674 shares by Orbimed Advisors Llc of Neuropace at 14.03 subject to Rule 1... at investing.com
24th of April 2024
Disposition of 1781 shares by Orbimed Advisors Llc of Neuropace at 14.06 subject to Rule 1... at MacroaxisInsider
22nd of April 2024
Disposition of 24609 shares by Orbimed Advisors Llc of Neuropace at 14.05 subject to Rule ... at MacroaxisInsider
18th of April 2024
Disposition of 2623 shares by Orbimed Advisors Llc of Neuropace at 14.06 subject to Rule 1... at investing.com
16th of April 2024
Disposition of 14069 shares by Orbimed Advisors Llc of Neuropace at 14.01 subject to Rule ... at MacroaxisInsider
12th of March 2024
The Latest Analyst Ratings For NeuroPace - NeuroPace - Benzinga at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuropace in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuropace's short interest history, or implied volatility extrapolated from Neuropace options trading.
Check out Neuropace Backtesting and Neuropace Hype Analysis. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.Note that the Neuropace information on this page should be used as a complementary analysis to other Neuropace's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Stocks Directory Find actively traded stocks across global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Neuropace's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 2.531 | Quarterly Revenue Growth 0.408 | Return On Assets (0.15) | Return On Equity (1.19) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.